Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared on LinkedIn:
“Programmable bacteria as cancer immunotherapy? A fascinating new study in Science Translational Medicine.
Congratulations to Mathieu Rouanne, Nicholas Arpaia, colleagues.
Engineered E. coli Nissle delivering CXCL13 directly into the bladder:
- Recruited and organized B- and T-cell immunity
- Induced tumor-specific antibodies
- Synergized with PD-1 blockade
- Produced durable tumor control and long-term survival in preclinical bladder cancer models
A compelling example of how synthetic biology could reshape the tumor immune microenvironment and expand the cancer immunotherapy toolbox.”
Title: Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models
Authors: Mathieu Rouanne, Noah Chen, Dylan L. Mariuzza, Zaofeng Yang, Fangda Li, Kenia de los Santos-Alexis, Thomas M. Savage, Rosa L. Vincent, Cathy L. Mendelsohn, Tal Danino, Nicholas Arpaia
Read The Full Article
